AOCI at other companies
Other financials
Where this comes from
Reported directly by MoonLake Immunotherapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax.
The official record: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about MoonLake Immunotherapeutics's aoci.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is MoonLake Immunotherapeutics's AOCI?
- MoonLake Immunotherapeutics (MLTX) reported AOCI of $322K in Q1 2026.
- How has MoonLake Immunotherapeutics's AOCI changed year-over-year?
- MoonLake Immunotherapeutics's AOCI decreased by 86.5% year-over-year, from $2.39M to $322K.
- What is the long-term trend for MoonLake Immunotherapeutics's AOCI?
- Over 4 years (2021 to 2025), MoonLake Immunotherapeutics's AOCI has grown at a 37.7% compound annual growth rate (CAGR), from -$168.18K to $604K.
- What does AOCI mean?
- Accumulated gains and losses bypassing the income statement — unrealized investment gains/losses, currency translation, pension adjustments, and hedge results.